Patent Results
Tranexamic Acid Formulations
- Published: May 24, 2011
- Filed: Feb 26, 2010
- Earliest Priority: Mar 04 2004
- Family: 5
- Cited Works: 102
- Cited by: 10
- Cites: 84
- Additional Info: Cited Works Full text Published
- Owner: Ferring B.v, Xanodyne Pharmaceuticals Inc, Mikart Inc
- Applicant: Ferring Bv
Tranexamic Acid Formulations
- Published: Sep 20, 2011
- Filed: Apr 30, 2009
- Earliest Priority: Mar 04 2004
- Family: 2
- Cited Works: 102
- Cited by: 8
- Cites: 81
- Additional Info: Cited Works Full text Published
- Owner: Ferring B.v, Mikart Inc, Xanodyne Pharmaceuticals Inc, Xanodyne Pharmaceuticals
- Applicant: Ferring Bv
Tranexamic Acid Formulations
- Published: Sep 25, 2012
- Filed: Aug 13, 2008
- Earliest Priority: Mar 04 2004
- Family: 10
- Cited Works: 101
- Cited by: 10
- Cites: 86
- Additional Info: Cited Works Full text Published
- Owner: Ferring B.v, Xenodyne Pharmaceuticals, Xanodyne Pharmaceuticals Inc, Mikart Inc
- Applicant: Moore Keith A, Heasley Ralph A, Greiwe Jeffrey S, Facemire John W, Modest Jason D, Ferring Bv
Uses And Compositions For Treatment Of Psoriasis
- Published: Nov 27, 2013
- Filed: Apr 10, 2007
- Earliest Priority: Apr 10 2006
- Family: 8
- Cited Works: 132
- Cited by: 1
- Cites: 53
- Sequences: 37
- Additional Info: Cited Works Published Sequence
- Applicant: Abbott Biotech Ltd
Tranexamic Acid Formulations With Reduced Adverse Effects
- Published: Mar 3, 2015
- Filed: Feb 3, 2006
- Earliest Priority: Jul 31 2003
- Family: 8
- Cited Works: 105
- Cited by: 0
- Cites: 102
- Additional Info: Cited Works Full text Published
- Owner: Ferring B.v, Xanodyne Pharmaceuticals, Xanodyne Pharmaceuticals Inc, Mikart Inc
- Applicant: Heasley Ralph A, Moore Keith A, Greiwe Jeffrey S, Facemire John W, Modest Jason D, Ferring Bv
Treatment Of Type 2 Diabetes Mellitus Patients
- Published: Sep 22, 2016
- Filed: Mar 18, 2016
- Earliest Priority: Mar 18 2015
- Family: 21
- Cited Works: 50
- Cited by: 0
- Cites: 1
- Sequences: 2
- Additional Info: Cited Works Full text Published Sequence
- Applicant: Sanofi Aventis Deutschland
Insulin Glargine/lixisenatide Fixed Ratio Formulation
- Published: Apr 24, 2018
- Filed: Dec 10, 2015
- Earliest Priority: Dec 12 2014
- Family: 22
- Cited Works: 939
- Cited by: 0
- Cites: 514
- Sequences: 2
- Additional Info: Cited Works Full text Published Sequence
- Owner: Sanofi-aventis Deutschland Gmbh, Saudi Arabian Oil Company
- Applicant: Sanofi Aventis Deutschland
Pharmaceutical Composition For Use In The Treatment Of A Neurodegenerative Disease
- Published: Jun 5, 2018
- Filed: May 4, 2016
- Earliest Priority: Sep 01 2011
- Family: 36
- Cited Works: 967
- Cited by: 0
- Cites: 507
- Sequences: 5
- Additional Info: Cited Works Full text Published Sequence
- Applicant: Sanofi Aventis Deutschland, Univ Ulster
Use Of Ave0010 For The Treatment Of Diabetes Mellitus Type 2
- Published: May 29, 2018
- Filed: Aug 15, 2016
- Earliest Priority: Aug 30 2010
- Family: 32
- Cited Works: 940
- Cited by: 0
- Cites: 520
- Sequences: 2
- Additional Info: Cited Works Full text Published Sequence
- Owner: Sanofi-aventis Deutschland Gmbh
- Applicant: Sanofi Aventis Deutschland
Pharmaceutical Combination For Improving Glycemic Control As Add-on Therapy To Basal Insulin
- Published: Nov 21, 2017
- Filed: May 9, 2012
- Earliest Priority: May 13 2011
- Family: 29
- Cited Works: 941
- Cited by: 2
- Cites: 510
- Sequences: 2
- Additional Info: Cited Works Full text Published Sequence
- Owner: Sanofi-aventis Deutschland Gmbh
- Applicant: Niemoeller Elisabeth, Silvestre Louise, Boka Gabor, Miossec Patrick, Sanofi Aventis Deutschland
{{::'analysis.preview.CITED_WORKS_ANALYSIS.title' | message}}
{{::'analysis.preview.view.full' | message}}
Add New Note
Sorry, you can't add a note to multiple items. You can add a note to your search as a saved query. Did you want to save this search and add a note to it?